The UK market has recently faced challenges, with the FTSE 100 and FTSE 250 indices slipping due to weak trade data from China, highlighting the interconnectedness of global economies. In such times, investors might consider exploring penny stocks—an investment area that remains relevant despite its somewhat outdated name. These smaller or newer companies can offer hidden value and potential growth, especially when they are built on solid financial foundations.
Top 10 Penny Stocks In The United Kingdom
| Name | Share Price | Market Cap | Rewards & Risks |
| Foresight Group Holdings (LSE:FSG) | £4.675 | £523.4M | ✅ 4 ⚠️ 0 View Analysis > |
| Warpaint London (AIM:W7L) | £2.24 | £180.96M | ✅ 3 ⚠️ 2 View Analysis > |
| Van Elle Holdings (AIM:VANL) | £0.40 | £43.28M | ✅ 4 ⚠️ 3 View Analysis > |
| Ingenta (AIM:ING) | £0.695 | £10.49M | ✅ 2 ⚠️ 2 View Analysis > |
| Integrated Diagnostics Holdings (LSE:IDHC) | $0.60 | $348.8M | ✅ 4 ⚠️ 2 View Analysis > |
| RWS Holdings (AIM:RWS) | £0.875 | £323.55M | ✅ 5 ⚠️ 2 View Analysis > |
| Alumasc Group (AIM:ALU) | £3.35 | £120.46M | ✅ 4 ⚠️ 1 View Analysis > |
| Begbies Traynor Group (AIM:BEG) | £1.22 | £194.23M | ✅ 4 ⚠️ 3 View Analysis > |
| Croma Security Solutions Group (AIM:CSSG) | £0.75 | £10.33M | ✅ 3 ⚠️ 4 View Analysis > |
| Braemar (LSE:BMS) | £2.56 | £78M | ✅ 3 ⚠️ 3 View Analysis > |
Click here to see the full list of 295 stocks from our UK Penny Stocks screener.
Let's uncover some gems from our specialized screener.
Kromek Group (AIM:KMK)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Kromek Group plc, with a market cap of £39.95 million, develops, manufactures, and sells radiation detection components and devices for advanced imaging, CBRN detection, and biological threat detection markets.
Operations: Kromek Group generates revenue from two primary segments: Advanced Imaging, contributing £27.83 million, and CBRN/Biological-Threat Detection, contributing £7.66 million.
Market Cap: £39.95M
Kromek Group plc has demonstrated significant financial improvement, transitioning to profitability with a net income of £3.75 million for the year ending April 2025, compared to a loss previously. The company benefits from strong short-term asset coverage over liabilities and reduced debt levels, maintaining more cash than total debt. However, its Return on Equity remains low at 7.2%, and interest coverage by EBIT is slightly below ideal levels. Recent contracts with the UK Ministry of Defence and Siemens Medical Solutions highlight strategic growth in revenue streams across advanced imaging and CBRN detection segments, supporting future revenue expectations despite forecasted earnings decline.
- Take a closer look at Kromek Group's potential here in our financial health report.
- Explore Kromek Group's analyst forecasts in our growth report.
Next 15 Group (AIM:NFG)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Next 15 Group plc provides customer insight, delivery, engagement, and business transformation services across the UK, Africa, the US, Europe, and the Middle East with a market cap of £273.51 million.
Operations: The company's revenue is derived from four main segments: Customer Engage (£340.56 million), Customer Insight (£73.87 million), Customer Delivery (£171.19 million), and Business Transformation (£144.19 million).
Market Cap: £273.51M
Next 15 Group plc, with a market cap of £273.51 million, presents a mixed picture for investors in penny stocks. The company has experienced significant profit growth over the past five years but faced negative earnings growth recently due to a large one-off loss of £16.8 million. Despite trading at 73% below its estimated fair value, it struggles with short-term liabilities exceeding assets and an unstable dividend track record. However, its debt is well covered by operating cash flow and interest payments are adequately managed by EBIT. Recent board changes could impact strategic direction moving forward.
- Click to explore a detailed breakdown of our findings in Next 15 Group's financial health report.
- Gain insights into Next 15 Group's outlook and expected performance with our report on the company's earnings estimates.
Springfield Properties (AIM:SPR)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Springfield Properties Plc, with a market cap of £117.85 million, operates in the United Kingdom as a house building company through its subsidiaries.
Operations: Springfield Properties does not report distinct revenue segments.
Market Cap: £117.85M
Springfield Properties Plc, with a market cap of £117.85 million, offers potential as a penny stock due to its strong earnings growth of 86.8% over the past year and trading at good value compared to peers. The company reported increased sales of £280.56 million and net income of £14.1 million for the fiscal year ended May 31, 2025. Its debt management is robust, with well-covered interest payments and reduced debt levels over time. However, its Return on Equity remains low at 8.2%, and earnings are forecasted to decline by an average of 5.3% annually over the next three years despite recent dividend increases reflecting financial stability.
- Jump into the full analysis health report here for a deeper understanding of Springfield Properties.
- Learn about Springfield Properties' future growth trajectory here.
Key Takeaways
- Dive into all 295 of the UK Penny Stocks we have identified here.
- Ready For A Different Approach? We've found 19 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Kromek Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com